<DOC>
	<DOC>NCT00277836</DOC>
	<brief_summary>MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.</brief_summary>
	<brief_title>Study Evaluating MST-997 in Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Documented diagnosis of malignant solid tumor with measurable disease Life expectancy of at least 12 weeks ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2 Recent major surgery, radiation therapy or anticancer treatment History of any other prior malignancy within last 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>malignant tumor</keyword>
</DOC>